Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs

Abstract

Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1 (Top1) is the sole target of the camptothecin (CPT) class of anticancer drugs. Over the last 20 years, multiple studies have shown Top1 activity is modulated by non-native DNA structures and this can lead to trapping of Top1 cleavage complexes (Top1cc) and conversion to DNA double strand breaks. Among the perturbations to DNA structure that generate Top1cc are nucleoside analogs that are incorporated into genomic DNA during replication including cytarabine, gemcitabine, and 5-fluoro-2’-deoxyuridine (FdU). We review the literature summarizing the role of Top1cc in mediating the DNA damaging and cytotoxic activities of nucleoside analogs. We also summarize studies demonstrating distinct differences between Top1cc induced by nucleoside analogs and CPTs, particularly with regard to DNA repair. Collectively, these studies demonstrate that, while Top1 is a common target for both Top1 poisons such as CPT and nucleoside analogs such as FdU, these agents are not redundant. In recent years, studies have shown that Top1 poisons and nucleoside analogs together with other anti-cancer drugs such as cisplatin cause replication stress and the DNA repair pathways that modulate the cytotoxic activities of these compounds are being elucidated. We present an overview of this evolving literature, which has implications for how targeting of Top1 with nucleoside analogs can be used more effectively for cancer treatment.

Keywords

DNA topoisomerase 1 / cancer chemotherapy / cytarabine / gemcitabine / fluoropyrimidine

References

[1] Wall ME.Camptothecin. Discovery to clinic..Ann N Y Acad Sci1996;803:1-12

[2] Champoux JJ.Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I..Ann N Y Acad Sci2000;922:56-64

[3] Vos SM,Schmidt BH.All tangled up: how cells direct, manage and exploit topoisomerase function..Nat Rev Mol Cell Biol2011;12:827-41 PMCID:PMC4351964

[4] Peter BJ,Hiasa H,Cozzarelli NR.The structure of supercoiled intermediates in DNA replication..Cell1998;94:819-27

[5] Liu LF.Supercoiling of the DNA template during transcription..Proc Natl Acad Sci U S A1987;84:7024-7 PMCID:PMC299221

[6] Stewart L,Qiu X,Champoux JJ.A model for the mechanism of human topoisomerase I..Science1998;279:1534-41

[7] Staker BL,Feese MD,Burgin AB Jr.The mechanism of topoisomerase I poisoning by a camptothecin analog..Proc Natl Acad Sci U S A2002;99:15387-92 PMCID:PMC137726

[8] Lin CP,Lyu YL.Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks..J Biol Chem2009;284:28084-92 PMCID:PMC2788859

[9] Regairaz M,Fu H,Tata N.Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes..J Cell Biol2011;195:739-49 PMCID:PMC3257568

[10] Sordet O,Guirouilh-Barbat J,Solier S.Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks..EMBO Rep2009;10:887-93 PMCID:PMC2726680

[11] Cristini A,Britton S,Huang SN.Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks..Cell Rep2019;28:3167-81.e6

[12] Rowinsky EK.Weekly topotecan: an alternative to topotecan’s standard daily x 5 schedule?.Oncologist2002;7:324-30

[13] Pourquier P,Fertala J,Park HJ.Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine..J Biol Chem1999;274:8516-23

[14] Daroui P,Li TK,Liu LF.Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death..J Biol Chem2004;279:14587-94

[15] Pourquier P,Gong SS,Rogler CE.Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro..Nucleic Acids Res1999;27:1919-25 PMCID:PMC148402

[16] Pourquier P,Kohlhagen G,Gupta M.Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I..J Biol Chem1997;272:7792-6

[17] Pourquier P,Kohlhagen G,Sharma A.Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects..J Biol Chem1997;272:26441-7

[18] Yeh YC,Ellis CA.Mammalian topoisomerase I has base mismatch nicking activity..J Biol Chem1994;269:15498-504

[19] Pommier Y,Pourquier P,Kroth H.Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages..Proc Natl Acad Sci U S A2000;97:2040-5 PMCID:PMC15750

[20] Antony S,Brooks PJ,Redinbo M.Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2’-deoxyguanosine..Nucleic Acids Res2004;32:5685-92 PMCID:PMC524309

[21] Lesher DT,Stewart L.8-Oxoguanine rearranges the active site of human topoisomerase I..Proc Natl Acad Sci U S A2002;99:12102-7 PMCID:PMC129405

[22] Galmarini CM,Dumontet C.Nucleoside analogues and nucleobases in cancer treatment..Lancet Oncol2002;3:415-24

[23] Gmeiner WH,James TL.Effect of cytarabine on the NMR structure of a model okazaki fragment from the SV40 genome..Biochemistry1999;38:1166-75

[24] Gmeiner WH,Pon RT.Cytarabine-induced destabilization of a model Okazaki fragment..Nucleic Acids Res1998;26:2359-65 PMCID:PMC147563

[25] Huang SY,Dalla Rosa I,Naumova A.TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs..Nucleic Acids Res2013;41:7793-803 PMCID:PMC3763526

[26] Bonven BJ,Westergaard O.A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin..Cell1985;41:541-51

[27] Pourquier P,Urasaki Y,Kohlhagen G.Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells..Proc Natl Acad Sci U S A2000;97:1885-90 PMCID:PMC26531

[28] Patel AG,Peterson KL,Schneider PA.Immunodetection of human topoisomerase I-DNA covalent complexes..Nucleic Acids Res2016;44:2816-26 PMCID:PMC4824114

[29] Cline SD.Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes..J Biol Chem1999;274:29740-3

[30] Loegering D,Hackbarth J,Roos-Mattjus P.Rad9 protects cells from topoisomerase poison-induced cell death..J Biol Chem2004;279:18641-7

[31] Sousa FG,Tang SW,Luna A.Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity..DNA Repair (Amst)2015;28:107-15 PMCID:PMC4385398

[32] Zoppoli G,Leo E,Varma S.Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents..Proc Natl Acad Sci U S A2012;109:15030-5 PMCID:PMC3443151

[33] Murai J,Leo E,Redon CE.SLFN11 Blocks Stressed Replication Forks Independently of ATR..Mol Cell2018;69:371-84.e6 PMCID:PMC5802881

[34] Al Abo M,Liu X,Huang SY.TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors..Mol Cancer Ther2017;16:2543-51 PMCID:PMC5971110

[35] Mini E,Caciagli B,Mazzei T.Cellular pharmacology of gemcitabine..Ann Oncol.2006;17 Suppl 5:v7-12

[36] Huang P,Hertel LW,Plunkett W.Action of 2’,2’-difluorodeoxycytidine on DNA synthesis..Cancer Res1991;51:6110-7

[37] Konerding D,Trump E,Marky LA.NMR structure of a gemcitabine-substituted model Okazaki fragment..Biochemistry2002;41:839-46

[38] Gmeiner WH.Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity..Biopolymers2002;65:180-9

[39] Pourquier P,Kohlhagen G,Goldwasser F.Gemcitabine (2’,2’-difluoro-2’-deoxycytidine), an antimetabolite that poisons topoisomerase I..Clin Cancer Res2002;8:2499-504

[40] An Q,Lindahl T.5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity..Cancer Res2007;67:940-5

[41] Ensminger WD,Raso V,Glode M.A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil..Cancer Res1978;38:3784-92

[42] Gmeiner WH.Novel chemical strategies for thymidylate synthase inhibition..Curr Med Chem2005;12:191-202

[43] Saif MW,Mehra R,Diasio RB.Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: experience of 4-years..Pak J Med Sci2007;23:832-9 PMCID:PMC2563423

[44] Dominijanni A.Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations..Cancer Drug Resist2018;1:48-58 PMCID:PMC6320232

[45] Gmeiner WH,Milligan C,Pardee TS.The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence..Future Oncol2016;12:2009-20 PMCID:PMC4992963

[46] Liao ZY,Zhang HL,Antony S.A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes..Cancer Res2005;65:4844-51

[47] Gmeiner WH,Pommier Y.Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons..Mol Cancer Ther2010;9:3105-14 PMCID:PMC3059097

[48] Pardee TS,Jennings-Gee J,Gmeiner WH.The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells..Oncotarget2014;5:4170-9 PMCID:PMC4147314

[49] Holbeck SL,Doroshow JH.Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines..Mol Cancer Ther2010;9:1451-60 PMCID:PMC2868078

[50] Gmeiner WH,Pon RT,Pommier Y.Structural basis for topoisomerase I inhibition by nucleoside analogs..Nucleosides Nucleotides Nucleic Acids2003;22:653-8

[51] Gmeiner WH,Olsen CM.The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs..J Nucleic Acids2011;2011:631372 PMCID:PMC3166759

[52] Jennings-Gee J,Gmeiner WH.Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity..Exp Hematol2013;41:180-8.e4 PMCID:PMC3660094

[53] Gmeiner WH,Pommier Y.F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death..Future Oncol2016;12:2183-8 PMCID:PMC5551924

[54] Das BB,Murai J,Ame JC.PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage..Nucleic Acids Res2014;42:4435-49 PMCID:PMC3985661

[55] Pardee TS,Jennings-Gee J,Gmeiner WH.Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity..Blood2012;119:3561-70 PMCID:PMC3325043

[56] Gmeiner WH,Bourland JD,Smith TL.F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy..J Clin Oncol Res2014;2:pii:1028 PMCID:PMC4442609

[57] Gmeiner WH,Gibo D,Milligan C.Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors..J Neurooncol2014;116:447-54 PMCID:PMC3905194

[58] Wahner Hendrickson AE,Hartmann LC,Northfelt DW.A phase I clinical trial of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors..Clin Cancer Res2018;24:744-52

[59] Murai J,Miettinen M.Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies..Pharmacol Ther2019;201:94-102 PMCID:PMC6708787